1Mes·

CAGRISEMA DEMONSTRATES SUPERIOR WEIGHT LOSS IN ADULTS WITH OBESITY OR OVERWEIGHT IN THE REDEFINE 1 TRIAL

Achieved its primary endpoint by demonstrating a statistically significant and superior weight loss at week 68 with CagriSema versus placebo; CagriSema achieved a superior weight loss of 22.7% after 68 weeks compared to a reduction of 11.8% with cagrilintide 2.4 mg

$LLY long on this?

6 Commenti

Tino@parlania

1Mes

whats bad about this news exactly for novo?

•

Aktien Stammtisch@Aktien_Stammtisch

1Mes

@parlania Expectations were higher than 22.7% weight loss

••

Tino@parlania

1Mes

@Aktien_Stammtisch yes 25%... because of 2.3% the -30% plummet???

••

Aktien Stammtisch@Aktien_Stammtisch

1Mes

@parlania yes seems to be slowly becoming an exaggeration

••

market_maverick_740@market_maverick_740

1Mes

@parlania Bought.

•

Aktien Stammtisch@Aktien_Stammtisch

1Mes

Notably, 40.4% of patients on CagriSema achieved ≥25% weight loss, significantly outperforming the other groups. The drug demonstrated a safe and well-tolerated profile with gastrointestinal side effects being mostly mild to moderate. Results from the REDEFINE 2 trial in type 2 diabetes patients are expected in H1 2025.

••